Welcome to our dedicated page for Masimo news (Ticker: MASI), a resource for investors and traders seeking the latest updates and insights on Masimo stock.
Masimo Corporation (NASDAQ: MASI) is a leading global medical technology company specializing in the development and manufacturing of innovative noninvasive patient monitoring technologies. For over 27 years, Masimo has been at the forefront of medical advancements, offering a wide array of sensors and devices that enhance patient care and safety. Their products are designed to provide healthcare professionals with critical information to improve clinical decision-making.
Masimo's core business is divided into two segments: healthcare and non-healthcare. The healthcare segment is the primary revenue generator, focusing on noninvasive patient monitoring technologies, hospital automation, connectivity solutions, and remote monitoring devices. Their clinically proven products are widely used in hospitals, emergency rooms, and clinical settings around the world.
The non-healthcare segment encompasses the consumer audio business, which includes the development, manufacturing, marketing, and licensing of premium and luxury audio sound products. This segment is known for its advanced audio integration technologies that appeal to audiophiles and general consumers alike.
Masimo's recent achievements include expanding their product portfolio with advanced remote monitoring solutions, partnering with leading healthcare organizations, and pioneering innovative technologies that address unsolvable medical challenges. Financially, the company is robust, showing consistent growth and a strong market presence.
Masimo’s dedication to improving lives is evident in their mission to save, extend, and enhance the quality of life across all demographics. Their innovative spirit attracts individuals who are passionate about making a significant impact in the medical field. As they continue to innovate, Masimo remains committed to providing top-tier products that meet the evolving needs of the healthcare industry.
Masimo (NASDAQ: MASI) has launched Dual SET® Pulse Oximetry for Root®, enhancing critical congenital heart disease (CCHD) screening. The CE-marked Masimo SET® MOC-9® module and the Eve™ application enable simultaneous pre- and post-ductal oxygen saturation measurements, improving newborn screening efficiency. CCHD affects 2.5 to 3 newborns per 1,000 births, necessitating early detection to reduce mortality and morbidity. Masimo's technology has shown increased screening sensitivity, enhancing newborn care and clinical workflows, although the new products are not yet FDA cleared for the U.S.
Masimo (NASDAQ: MASI) reported Q3 2021 financial results, highlighting product revenue of $307.4 million, a growth of 10.5% from Q3 2020. GAAP net income reached $57.8 million, or $1.00 per diluted share, up from $49.4 million, or $0.85 per share in the previous year. The company maintained strong operational performance with GAAP operating margins of 22.0% and non-GAAP margins at 23.0%. For full-year 2021, Masimo revised its guidance to a total revenue of $1.230 billion, representing a projected growth of 7.5%.
Masimo (NASDAQ: MASI) presented findings at ANESTHESIOLOGY 2021, demonstrating the efficacy of its PVi® technology in managing fluid administration during major oncosurgery. Researchers from Rajiv Gandhi Cancer Institute found that patients guided by PVi received significantly less fluid and exhibited fewer B-lines, indicators of extravascular lung water (EVLW), without a decrease in postoperative oxygenation compared to those using conventional CVP methods. These results highlight PVi's potential for enhanced patient care in surgical settings.
Masimo (NASDAQ: MASI) will announce its third quarter 2021 financial results on October 26, 2021, after market close. The results will be discussed in a conference call scheduled for 1:30 p.m. PT (4:30 p.m. ET), featuring CEO Joe Kiani and CFO Micah Young. Masimo is a renowned medical technology company focused on noninvasive monitoring technologies aimed at improving patient outcomes and reducing costs. The company’s drive for innovation has made its technologies integral in leading hospitals globally.
Masimo's Patient SafetyNet™ is enhancing healthcare efficiency at University Hospitals in Cleveland by tackling nurse burnout and boosting workflows. Amid rising nursing turnover—with 80% of hospitals reporting increased rates—this innovative system significantly decreases the time between obtaining and documenting patient vital signs from over 60 minutes to less than 5 minutes, saving one FTE per shift. Clinical studies support the system's effectiveness in improving patient monitoring and outcomes, marking a pivotal step in addressing nursing shortages exacerbated by the COVID-19 pandemic.
Masimo (NASDAQ: MASI) announced a study published in the European Journal of Pediatrics, highlighting the effectiveness of its EMMA® Portable Capnograph for monitoring mechanically ventilated preterm infants. Conducted by Dr. Masashi Hotta and colleagues in Japan, the study involved 40 neonates and found that 80% in the EMMA group maintained appropriate carbon dioxide levels compared to 42% in a control group. The research emphasizes EMMA's potential in neonatal care, although it currently lacks FDA clearance for neonates.
Masimo (NASDAQ: MASI) announced that its Founder and CEO, Joe Kiani, has been appointed by President Biden to the President’s Council of Advisors on Science and Technology (PCAST). This council aims to provide the President with scientific advice on various pressing issues, including public health and climate change. The PCAST comprises 30 diverse members with extensive expertise in science and technology. Kiani expressed enthusiasm about collaborating with this distinguished group to enhance healthcare and innovation.
Masimo (NASDAQ: MASI) announced the CE marking and launch of its innovative rainbow® SuperSensor™ in Europe, designed for single-patient use. This advanced sensor can monitor 12 physiological parameters noninvasively, including SpO2, total hemoglobin, and respiration rate. The SuperSensor enhances continuous monitoring capabilities, allowing clinicians to assess patients' conditions more accurately. With proven effectiveness in improving patient outcomes, this technology aims to bolster patient safety and streamline care in critical settings.
Masimo (NASDAQ: MASI) will participate in the Morgan Stanley 19th Annual Global Healthcare Conference on September 9, 2021, at 4:15 p.m. ET. A live webcast will be available on the company's website, with a replay following the event. Masimo is a leader in medical technology, known for its innovative monitoring solutions including Masimo SET® pulse oximetry, which has been validated in over 100 studies. The technology aims to enhance patient outcomes and minimize healthcare costs, with significant usage across major hospitals.
Masimo (NASDAQ: MASI) announced a study revealing that the Oxygen Reserve Index (ORi) may provide early warnings for hypoxemia during endotracheal intubation (ETI) in ICU patients. Conducted by researchers at Centre Hospitalier Universitaire in France, the study showed a median of 81 seconds between ORi decrease and oxygen saturation drop, allowing for preventive actions. The study concluded that a higher ORi during preoxygenation is independently protective against hypoxemia. However, ORi lacks FDA clearance in the U.S.
FAQ
What is the current stock price of Masimo (MASI)?
What is the market cap of Masimo (MASI)?
What is Masimo Corporation's main business?
How long has Masimo Corporation been in operation?
What are the key segments of Masimo's business?
What products does Masimo offer?
What makes Masimo's products unique?
Who uses Masimo's healthcare products?
What recent achievements has Masimo Corporation accomplished?
What is the financial status of Masimo Corporation?
What is Masimo's mission?
Where can I find the latest news about Masimo Corporation?
